クローン病の患者におけるウステキヌマブの長期的な有効性と安全性:実用的な証拠
Yumei Wu1, Linlin Zhou1, Mengqi Huang1
1Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Expert opinion on biological therapy
|September 2, 2025
まとめ
Ustekinumab (UST) は,クローン病 (CD) の患者で有効性を示し,52週間で70. 95%の臨床寛解率を示した. 前回の生物学的使用,早期のCRP減少,およびヘモグロビンレベルは,この現実世界の中国のコホートにおける寛解を予測しています.
科学分野:
- 胃腸内科
- 免疫学
- 薬理学について
背景:
- ウステキヌマブ (UST) は,IL-12/IL-23受容体アンタゴニストで,クローン病 (CD) の治療に承認されています.
- 中国人のCD患者におけるUSTの有効性と安全性に関する長期の実際のデータは限られている.
研究 の 目的:
- 中国のCD患者集団におけるUSTの長期的な有効性,持続性,および安全性を評価する.
- USTで治療されたCD患者の臨床寛解の予測要因を特定する.
主な方法:
- 単一センターで観察した研究です
- 2020年1月から2024年1月までUSTで治療を受けた348人のCD患者を含む.
- 寛解率と予測変数を含む,人口統計学的,臨床的パラメータと結果の分析.
主要な成果:
- 52週目には臨床寛解が70. 95%,内視寛解が24. 68%,CRP正常化が54. 11%,FCP正常化が48. 57%であった.
- 前回の生物学的暴露,第8週におけるCRP減少,および出血血糖値は,臨床寛解の独立予測指標であった.
- UST治療の平均期間は172週間でした.
結論:
- Ustekinumabは,中国人のCD患者に好ましい有効性,持続性,および安全性を示しています.
- 早期のC反応性タンパク質の減少と初期ヘモグロビンのレベルは52週に臨床寛解の達成と関連しています.
- 前回の生物学的曝露も治療の成功の重要な予測因子です.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease II: Crohn's Disease
375
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
375
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185


